



doseology

Doseology Names CFO and Appoints New Board Member

Vernon, British Columbia, January 28, 2022 – **Doseology Sciences Inc.** (CSE: **MOOD**) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the appointment of Peter Geh as Chief Financial Officer, effective January 26, 2022, and the addition of Harbir Toor as Director and Independent Audit Chair, effective January 27, 2022.

Peter Geh is an experienced financial and accounting executive based in Kelowna, B.C. As a Chartered Professional Accountant with over fifteen years of corporate experience, he has guided several Canadian companies through growth stages in the healthtech, retail, and manufacturing industries.

Peter spent over ten years in public practice accounting working with entities in the public, private and not-for-profit sectors. As VP Finance of a Canadian tech company, Peter oversaw revenue growth of over 400 percent and staff growth of 75 percent during a two-year period.

“We’re very fortunate to have Peter join our team at this critical stage”, said Maryam Marissen, Doseology CEO. “His experience across several related industries in British Columbia, plus his ability to hone in on financial details while maintaining high-level perspective make him the ideal CFO for Doseology.”

On the appointment, Peter Geh remarked, “I am very excited about the opportunity to be a part of such an innovative, growing company like Doseology. To help guide us forward, I plan to leverage my specialties in strategic planning and execution, financial risk management, and shareholder value creation. I have a passion for helping companies of this size because I can take a very hands-on approach to financial management. I’m looking forward to working towards our goals with the Doseology team.”

Doseology Sciences Inc. has also named Harbir Toor, CPA, CA, as the Independent Audit Chair of the Board of Directors. Ms. Toor has 25 years of experience in strategic planning, risk management, governance, capital raises, and financial accounting. She began her career in audit at KPMG and most recently has held several senior executive positions in both private and publicly listed companies, including VP Finance and CFO in the biopharmaceutical and life sciences industries.

CEO Maryam Marissen commented, “Harbir is a tremendous asset for a diversified life sciences company such as ours. She has guided several other Canadian biotech

and pharmaceutical companies in their financial and operational growth phases, and that relevant experience is truly invaluable.”

Ms. Marissen thanks Interim CFO Alex McAulay for his service to the Company. Doseology also announces that Mr. Gordon Jang has resigned as a Director and Independent Audit Chair of the Company, effective January 27, 2022. Mr. Jang will remain an advisor on Doseology’s financial matters and strategic decisions. Doseology wishes to thank Gordon for his valuable service and insight.

To support the Company’s mission and create profitable revenue streams in growing markets, Doseology is pursuing the cultivation of functional mushrooms, distribution of its medicinal mushroom nootropics products, and establishing clinical services. In November, the company applied for a Health Canada Dealer’s License, which upon approval will allow for psilocybin-related research and cultivation.

To learn more about the Doseology management team and see recent company news, visit [Doseology Investor Resources](#).

On Behalf of the Board of Directors

Maryam Marissen
Chief Executive Officer
Doseology Sciences Inc.
maryam@doseology.com

About Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: **MOOD**) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:

Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements

This corporate update contains statements which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions

and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company's securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE
UNITED STATES